Nothing Special   »   [go: up one dir, main page]

You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (1,389)

Search Parameters:
Keywords = cancer survivors

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 934 KiB  
Article
Impact of a Physical Exercise and Health Education Program on Metabolic Syndrome and Quality of Life in Postmenopausal Breast Cancer Women Undergoing Adjuvant Treatment with Aromatase Inhibitors
by Pedro Cespedes, Francisco M. Martínez-Arnau, María Dolores Torregrosa, Omar Cauli and Cristina Buigues
Medicina 2024, 60(11), 1893; https://doi.org/10.3390/medicina60111893 (registering DOI) - 18 Nov 2024
Abstract
Background and Objectives: Adjuvant treatment with aromatase inhibitors (AIs) in breast cancer (BC) survivors can cause adverse effects such as metabolic syndrome (MS) (insulin resistance, central obesity, atherogenic dyslipidemia, and hypertension) associated with morbidity and premature mortality. We evaluate the effect of [...] Read more.
Background and Objectives: Adjuvant treatment with aromatase inhibitors (AIs) in breast cancer (BC) survivors can cause adverse effects such as metabolic syndrome (MS) (insulin resistance, central obesity, atherogenic dyslipidemia, and hypertension) associated with morbidity and premature mortality. We evaluate the effect of a multimodal program based on physical exercise and health education on MS and health-related quality of life (QoL) in postmenopausal women with BC under AIs. Methods: A total of 56 postmenopausal women, diagnosed with BC, aged 60 years or older (mean age 67.2 years) and on hormonal treatment with AIs, were included in the multimodal physical exercise and health education program, and evaluated before and after their participation. The assessment of the five criteria of the MS included the following: waist circumference, high blood pressure, fasting glucose, triglycerides, and high-density lipoprotein cholesterol. Two main instruments were used to evaluate the impact of the intervention on QoL: the EORTC QLQ C30 (questionnaire for cancers in general) and the EORTC QLQ BR23 (specifically for breast cancer patients). The EuroQol 5D (EQ-5D) was also used to compare these results. Results: The percentage of women meeting the MS criteria was 37.7% at baseline and fell to 15.1% at 3 months after the intervention (p = 0.02). The intervention significantly reduced hypertension (p < 0.001), central obesity (p < 0.001), and the concentration of triglycerides (p = 0.016). No significant changes were observed in fasting glucose and HDL concentration. A statistically significant improvement was found in QoL (on both the QLQ30 and BR23 scales). A multivariate regression model analysis identified marital status (being married) (95% CI: 1.728–131.615, p = 0.014), and percentage of attendance at health education sessions (95% CI: 1.010–1.211, p = 0.029) as positive predictive variables of improvement in MS. Conclusions: The implementation of multimodal, community-based programs of physical exercise and health education improve the prevalence of MS and specific criteria of MS and QoL in postmenopausal women with breast cancer receiving AI treatment. Full article
(This article belongs to the Section Obstetrics and Gynecology)
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>) Correlation between number of daily medication and number of metabolic syndrome criteria before the intervention. (<b>B</b>) Correlation between BMI (Body mass index) before the intervention and number of metabolic syndrome criteria before the intervention.</p>
Full article ">Figure 2
<p>Evaluation of metabolic syndrome based on the presence of the number of criteria after the program compared at the baseline. MS: metabolic syndrome. The presence of metabolic syndrome was assessed if they met at least 3 of the 5 criteria according to the NCEP-ATP III definitions [<a href="#B33-medicina-60-01893" class="html-bibr">33</a>] (* significant difference obtained with the McNemar test; <span class="html-italic">p</span> = 0.002).</p>
Full article ">
17 pages, 833 KiB  
Review
Optimizing Reproductive Options for Young Women with Cervical Cancer
by Giulia Mattei, Francesco Iaculli, Fabiana Carbone, Alessandro Mondo and Ludovico Muzii
Reprod. Med. 2024, 5(4), 263-279; https://doi.org/10.3390/reprodmed5040023 (registering DOI) - 18 Nov 2024
Viewed by 257
Abstract
Cervical cancer is one of the leading causes of mortality in women of reproductive age. In recent years, the development of preventive and therapeutic strategies has significantly increased survival rates. While this represents an important medical achievement, it has also raised a major [...] Read more.
Cervical cancer is one of the leading causes of mortality in women of reproductive age. In recent years, the development of preventive and therapeutic strategies has significantly increased survival rates. While this represents an important medical achievement, it has also raised a major social issue regarding the need to ensure an adequate quality of life for surviving patients. Many of these women are left without their reproductive capacity at an age when their desire for motherhood has not yet been fulfilled. Infertility or subfertility in cancer survivors is actually a growing problem, complicated by the current trend of increasingly delaying pregnancy. The psychological effects of this issue can be devastating, sometimes even more so than the cancer diagnosis itself. Although today fertility-sparing surgeries can ensure excellent reproductive outcomes with minimal oncological risk, obstetric sequelae remain significant, and affected women often require specialized care pathways. Additionally, adequate counselling is still not provided to all patients who cannot access fertility-sparing treatments and who find themselves without hope. Reproductive medicine is therefore facing the modern challenge of offering concrete options to help these patients realize their desire for motherhood. The aim of this article is to provide an overview of the therapeutic options available to young women facing an early- or later-stage diagnosis of cervical cancer. Full article
(This article belongs to the Special Issue Feature Papers in Reproductive Medicine 2024)
Show Figures

Figure 1

Figure 1
<p>Fertility-sparing surgery in early stages of cervical cancer. FIGO: Fédération Internationale de Gynécologie et d’Obstétrique; LEEP: loop electrosurgical excision procedure; NACT: neoadjuvant chemotherapy.</p>
Full article ">Figure 2
<p>Fertility-sparing surgery options in advanced stages of cervical cancer. NACT: neoadjuvant chemotherapy; FSS: Fertility-sparing Surgery; CTRT: concurrent chemoradiotherapy.</p>
Full article ">
14 pages, 1351 KiB  
Article
Movement Behaviors and Bone Biomarkers in Young Pediatric Cancer Survivors: A Cross-Sectional Analysis of the iBoneFIT Project
by Jose J. Gil-Cosano, Esther Ubago-Guisado, Francisco J. Llorente-Cantarero, Andres Marmol-Perez, Andrea Rodriguez-Solana, Juan F. Pascual-Gazquez, Maria E. Mateos, Jose R. Molina-Hurtado, Beatriz Garcia-Fontana, Pedro Henrique Narciso, Panagiota Klentrou and Luis Gracia-Marco
Nutrients 2024, 16(22), 3914; https://doi.org/10.3390/nu16223914 (registering DOI) - 16 Nov 2024
Viewed by 330
Abstract
Background/Objectives: This study aims to investigate the association of movement behaviors with irisin, sclerostin, and bone turnover markers in young pediatric cancer survivors. Methods: A total of 116 young pediatric cancer survivors (12.1 ± 3.3 years; 42% female) were recruited. Time spent in [...] Read more.
Background/Objectives: This study aims to investigate the association of movement behaviors with irisin, sclerostin, and bone turnover markers in young pediatric cancer survivors. Methods: A total of 116 young pediatric cancer survivors (12.1 ± 3.3 years; 42% female) were recruited. Time spent in movement behaviors over at least seven consecutive 24 h periods was measured by accelerometers (wGT3x-BT accelerometer, ActiGraph). Blood samples were collected at rest and serum was analyzed for irisin, sclerostin, cross-linked telopeptide of type I collagen (CTX), procollagen type I amino-terminal propeptide (P1NP), total osteocalcin (OC), alkaline phosphatase (ALP), 25-hydroxyvitamin D, parathyroid hormone (PTH), calcium, phosphorous, and magnesium. Results: Irisin and sclerostin were not significantly correlated with bone turnover markers. Sedentary time was negatively correlated with the P1NP (r = −0.411, p = 0.027) and total OC (r = −0.479, p = 0.015) Z-scores, whereas moderate-to-vigorous physical activity was positively correlated with the P1NP (r = 0.418, p = 0.024) and total OC (r = 0.478, p = 0.016) Z-scores. Moreover, total physical activity was positively correlated with the total OC Z-score (r = 0.448, p = 0.025). Finally, the uncoupling index [CTX/P1NP] was positively correlated with sedentary time (r = 0.424, p = 0.012) and negatively correlated with light physical activity (r = −0.352, 0.041). Conclusions: Reducing sedentary time and increasing physical activity may favor bone formation over resorption in young pediatric cancer survivors. Full article
Show Figures

Figure 1

Figure 1
<p>Flowchart of the study. PA, physical activity; PTH, parathyroid hormone; ALP, alkaline phosphatase; CTX, collagen type I cross-linked C-telopeptide; P1NP, procollagen type I N-terminal propeptide; OC, osteocalcin.</p>
Full article ">Figure 2
<p>Bone marker plot with 95% confidence ellipsis from (<b>A</b>) CTX/P1NP and (<b>B</b>) CTX/OC.</p>
Full article ">Figure 3
<p>Relationships of circulating sclerostin (panel (<b>A</b>–<b>C</b>)) and irisin (panel (<b>D</b>–<b>F</b>)) with bone turnover markers. CTX, collagen type I cross-linked C-telopeptide; P1NP, procollagen type I N-terminal propeptide; OC, osteocalcin.</p>
Full article ">Figure 4
<p>Relationships between movement behaviors and the uncoupling index CTX/P1NP (panel (<b>A</b>–<b>D</b>)) and the uncoupling index CTX/OC (panel (<b>E</b>–<b>H</b>)). SB, sedentary behavior; LPA, light physical activity; MVPA, moderate-to-vigorous physical activity; CTX, collagen type I cross-linked C-telopeptide; P1NP, procollagen type I N-terminal propeptide; OC, osteocalcin. Boldface indicates statistical significance.</p>
Full article ">
18 pages, 5164 KiB  
Article
Redox Imbalance and Antioxidant Defenses Dysfunction: Key Contributors to Early Aging in Childhood Cancer Survivors
by Vanessa Cossu, Nadia Bertola, Chiara Fresia, Federica Sabatini and Silvia Ravera
Antioxidants 2024, 13(11), 1397; https://doi.org/10.3390/antiox13111397 - 15 Nov 2024
Viewed by 256
Abstract
Survival rates for childhood cancer survivors (CCS) have improved, although they display a risk for early frailty due to the long-term effects of chemo/radiotherapy, including early aging. This study investigates antioxidant defenses and oxidative damage in mononuclear cells (MNCs) from CCS, comparing them [...] Read more.
Survival rates for childhood cancer survivors (CCS) have improved, although they display a risk for early frailty due to the long-term effects of chemo/radiotherapy, including early aging. This study investigates antioxidant defenses and oxidative damage in mononuclear cells (MNCs) from CCS, comparing them with those from age-matched and elderly healthy individuals. Results show impaired antioxidant responses and increased oxidative stress in CCS MNCs, which exhibited uncoupled oxidative phosphorylation, leading to higher production of reactive oxygen species, similar to metabolic issues seen in elderly individuals. Key antioxidant enzymes, namely glucose-6-phosphate dehydrogenase, hexose-6-phosphate dehydrogenase, glutathione reductase, glutathione peroxidase, catalase, and superoxide dismutase, showed reduced activity, likely due to lower expression of nuclear factor erythroid 2–related factor 2 (Nrf2). This imbalance caused significant damage to lipids, proteins, and DNA, potentially contributing to cellular dysfunction and a higher risk of cancer recurrence. These oxidative and metabolic dysfunctions persist over time, regardless of cancer type or treatment. However, treatment with N-acetylcysteine improved Nrf2 expression, boosted antioxidant defenses, reduced oxidative damage, and restored oxidative phosphorylation efficiency, suggesting that targeting the redox imbalance could enhance long-term CCS health. Full article
Show Figures

Figure 1

Figure 1
<p>OxPhos efficiency, ROS production, and oxidative damage accumulation in MNCs isolated from CCS, age-matched healthy subjects, and elderly healthy controls. All data were obtained on MNCs isolated from age-matched healthy controls (&lt;10 y.o., <span class="html-italic">n</span> = 18; 11–20 y.o., <span class="html-italic">n</span> = 32; 21–40 y.o, <span class="html-italic">n</span> = 20), CCS of solid tumor (sCCS; &lt;10 y.o., <span class="html-italic">n</span> = 27; 11–20 y.o., <span class="html-italic">n</span> = 29; 21–40 y.o., <span class="html-italic">n</span> = 18), CCS of hematological tumors (hCCS; &lt;10 y.o., <span class="html-italic">n</span> = 25; 11–20 y.o., <span class="html-italic">n</span> = 28; 21–40 y.o., <span class="html-italic">n</span> = 22), healthy donors aged between 41–60 y.o., <span class="html-italic">n</span> = 19; healthy donors aged between 61–80 y.o., <span class="html-italic">n</span> = 25; healthy donors aged over 80 y.o., <span class="html-italic">n</span> = 22. (<b>A</b>) P/O value, an OxPhos efficiency marker, evaluated in the presence of pyruvate plus malate as respiring substrates; (<b>B</b>) Reactive oxygen species (ROS) production; (<b>C</b>) Malondialdehyde (MDA) intracellular concentration, as a lipid peroxidation marker; (<b>D</b>) 4-hydroxynonenal (4-HNE) intracellular concentration, as a lipid peroxidation marker; (<b>E</b>) 8-Hydroxy-2′-deoxyguanosine (8-OHdG) intracellular concentration, as a DNA oxidative damage marker; (<b>F</b>) Nitrotyrosine intracellular level, as a protein oxidative damage marker. **** indicates a <span class="html-italic">p</span> &lt; 0.0001. ##, ###, and #### indicate a <span class="html-italic">p</span> &lt; 0.01, 0.001, or 0.0001, respectively, between sCCS or hCCS and healthy donors aged 41–60 y.o. No significant differences were observed between CCS samples and healthy subjects aged between 61–80 y.o. and over 80 y.o.</p>
Full article ">Figure 2
<p>Intracellular level of oxidized and reduced forms of NADP and glutathione in MNCs isolated from CCS, age-matched healthy subjects, and elderly healthy controls. All data were obtained on MNCs isolated from age-matched healthy controls (&lt;10 y.o., <span class="html-italic">n</span> = 18; 11–20 y.o., <span class="html-italic">n</span> = 32; 21–40 y.o., <span class="html-italic">n</span> = 20), CCS of solid tumor (sCCS; &lt;10 y.o., <span class="html-italic">n</span> = 27; 11–20 y.o., <span class="html-italic">n</span> = 29; 21–40 y.o., <span class="html-italic">n</span> = 18), CCS of hematological tumors (hCCS; &lt;10 y.o., <span class="html-italic">n</span> = 25; 11–20 y.o., <span class="html-italic">n</span> = 28; 21–40 y.o., <span class="html-italic">n</span> = 22), healthy donors aged between 41–60 y.o., <span class="html-italic">n</span> = 19; healthy donors aged between 61–80 y.o., <span class="html-italic">n</span> = 25; healthy donors aged over 80 y.o., <span class="html-italic">n</span> = 22. (<b>A</b>) Total intracellular concentration of reduced and oxidized forms of NADP; (<b>B</b>) Ratio between NADPH and NADP; (<b>C</b>) Total intracellular concentration of reduced and oxidized forms of glutathione (GSH + GSSG); (<b>D</b>) Ratio between GSH and GSSG. **** indicates a <span class="html-italic">p</span> &lt; 0.0001. #, ##, ###, and #### indicate a <span class="html-italic">p</span> &lt; 0.05, 0.01, 0.001, or 0.0001, respectively, between sCCS or hCCS and healthy donors aged 61–80 y.o. No significant differences were observed between CCS samples and healthy subjects over 80 y.o.</p>
Full article ">Figure 3
<p>Activity and protein expression of G6PD, H6PD, GR, and GPX in MNCs isolated from CCS, age-matched healthy subjects, and elderly healthy controls. Data reported in Panels (<b>A</b>–<b>D</b>) were obtained on MNCs isolated from age-matched healthy controls (&lt;10 y.o., <span class="html-italic">n</span> = 18; 11–20 y.o., <span class="html-italic">n</span> = 32; 21–40 y.o., <span class="html-italic">n</span> = 20), CCS of solid tumor (sCCS; &lt;10 y.o., <span class="html-italic">n</span> = 27; 11–20 y.o., <span class="html-italic">n</span> = 29; 21–40 y.o., <span class="html-italic">n</span> = 18), CCS of hematological tumors (hCCS; &lt;10 y.o., <span class="html-italic">n</span> = 25; 11–20 y.o., <span class="html-italic">n</span> = 28; 21–40 y.o., <span class="html-italic">n</span> = 22), healthy donors aged between 41–60 y.o., <span class="html-italic">n</span> = 19; healthy donors aged between 61–80 y.o., <span class="html-italic">n</span> = 25; healthy donors aged over 80 y.o., <span class="html-italic">n</span> = 22. Data reported in Panels (<b>E</b>–<b>I</b>) are representative of three independent experiments, each on <span class="html-italic">n</span> = 3 age-matched healthy donors (&lt;40 y.o.); <span class="html-italic">n</span> = 3 (CCS &lt; 40 y.o.), and <span class="html-italic">n</span> = 3 elderly healthy subjects (&gt;60 y.o.) (<b>A</b>) G6PD activity; (<b>B</b>) H6PD activity; (<b>C</b>) GR activity; (<b>D</b>) GPx activity; (<b>E</b>) Representative Western blot signals of G6PD, H6PD, GR, and GPX. Actin was evaluated as a housekeeping signal. (<b>F</b>) Densitometric analysis of G6PD signal normalized against actin signal; (<b>G</b>) Densitometric analysis of H6PD signal normalized against actin signal; (<b>H</b>) Densitometric analysis of GR signal normalized against actin signal; (<b>I</b>) Densitometric analysis of GPx signal normalized against actin signal. ROD = Relative Optical Density. *, **** indicate a <span class="html-italic">p</span> &lt; 0.05, 0.0001. In panels (<b>A</b>–<b>D</b>), #, ##, and ### indicate a <span class="html-italic">p</span> &lt; 0.05, 0.01, or 0.001, respectively, between sCCS or hCCS and healthy donors over 80 y.o.</p>
Full article ">Figure 3 Cont.
<p>Activity and protein expression of G6PD, H6PD, GR, and GPX in MNCs isolated from CCS, age-matched healthy subjects, and elderly healthy controls. Data reported in Panels (<b>A</b>–<b>D</b>) were obtained on MNCs isolated from age-matched healthy controls (&lt;10 y.o., <span class="html-italic">n</span> = 18; 11–20 y.o., <span class="html-italic">n</span> = 32; 21–40 y.o., <span class="html-italic">n</span> = 20), CCS of solid tumor (sCCS; &lt;10 y.o., <span class="html-italic">n</span> = 27; 11–20 y.o., <span class="html-italic">n</span> = 29; 21–40 y.o., <span class="html-italic">n</span> = 18), CCS of hematological tumors (hCCS; &lt;10 y.o., <span class="html-italic">n</span> = 25; 11–20 y.o., <span class="html-italic">n</span> = 28; 21–40 y.o., <span class="html-italic">n</span> = 22), healthy donors aged between 41–60 y.o., <span class="html-italic">n</span> = 19; healthy donors aged between 61–80 y.o., <span class="html-italic">n</span> = 25; healthy donors aged over 80 y.o., <span class="html-italic">n</span> = 22. Data reported in Panels (<b>E</b>–<b>I</b>) are representative of three independent experiments, each on <span class="html-italic">n</span> = 3 age-matched healthy donors (&lt;40 y.o.); <span class="html-italic">n</span> = 3 (CCS &lt; 40 y.o.), and <span class="html-italic">n</span> = 3 elderly healthy subjects (&gt;60 y.o.) (<b>A</b>) G6PD activity; (<b>B</b>) H6PD activity; (<b>C</b>) GR activity; (<b>D</b>) GPx activity; (<b>E</b>) Representative Western blot signals of G6PD, H6PD, GR, and GPX. Actin was evaluated as a housekeeping signal. (<b>F</b>) Densitometric analysis of G6PD signal normalized against actin signal; (<b>G</b>) Densitometric analysis of H6PD signal normalized against actin signal; (<b>H</b>) Densitometric analysis of GR signal normalized against actin signal; (<b>I</b>) Densitometric analysis of GPx signal normalized against actin signal. ROD = Relative Optical Density. *, **** indicate a <span class="html-italic">p</span> &lt; 0.05, 0.0001. In panels (<b>A</b>–<b>D</b>), #, ##, and ### indicate a <span class="html-italic">p</span> &lt; 0.05, 0.01, or 0.001, respectively, between sCCS or hCCS and healthy donors over 80 y.o.</p>
Full article ">Figure 4
<p>Activity and protein expression of SOD and CAT in MNCs isolated from CCS, age-matched healthy subjects, and elderly healthy controls. Data reported in Panels (<b>A</b>,<b>B</b>) were obtained on MNCs isolated from age-matched healthy controls (&lt;10 y.o., <span class="html-italic">n</span> = 18; 11–20 y.o., <span class="html-italic">n</span> = 32; 21–40 y.o., <span class="html-italic">n</span> = 20), CCS of solid tumor (sCCS; &lt;10 y.o., <span class="html-italic">n</span> = 27; 11–20 y.o., <span class="html-italic">n</span> = 29; 21–40 y.o., <span class="html-italic">n</span> = 18), CCS of hematological tumors (hCCS; &lt;10 y.o., <span class="html-italic">n</span> = 25; 11–20 y.o., <span class="html-italic">n</span> = 28; 21–40 y.o., <span class="html-italic">n</span> = 22), healthy donors aged between 41–60 y.o., <span class="html-italic">n</span> = 19; healthy donors aged between 61–80 y.o., <span class="html-italic">n</span> = 25; healthy donors aged over 80 y.o., <span class="html-italic">n</span> = 22. Data reported in Panels (<b>C</b>–<b>F</b>) are representative of three independent experiments, each on <span class="html-italic">n</span> = 3 age-matched healthy donors (&lt;40 y.o); <span class="html-italic">n</span> = 3 (CCS &lt; 40 y.o.), and <span class="html-italic">n</span> = 3 elderly healthy subjects (&gt;60 y.o.). (<b>A</b>) SOD activity; (<b>B</b>) CAT activity; (<b>C</b>) Representative Western blot signals of SOD1 (cytosolic form), SOD2 (mitochondrial form), and CAT. Actin was evaluated as a housekeeping signal. (<b>D</b>) Densitometric analysis of SOD1 signal normalized against actin signal; (<b>E</b>) Densitometric analysis of SOD2 signal normalized against actin signal; (<b>F</b>) Densitometric analysis of CAT signal normalized against actin signal. ROD = Relative Optical Density. *, **** indicate a <span class="html-italic">p</span> &lt; 0.05, 0.0001. In panels (<b>A</b>,<b>B</b>), ##, and ### indicate a <span class="html-italic">p</span> &lt; 0.01, or 0.001, respectively, between sCCS or hCCS and healthy donors over 80 y.o.</p>
Full article ">Figure 4 Cont.
<p>Activity and protein expression of SOD and CAT in MNCs isolated from CCS, age-matched healthy subjects, and elderly healthy controls. Data reported in Panels (<b>A</b>,<b>B</b>) were obtained on MNCs isolated from age-matched healthy controls (&lt;10 y.o., <span class="html-italic">n</span> = 18; 11–20 y.o., <span class="html-italic">n</span> = 32; 21–40 y.o., <span class="html-italic">n</span> = 20), CCS of solid tumor (sCCS; &lt;10 y.o., <span class="html-italic">n</span> = 27; 11–20 y.o., <span class="html-italic">n</span> = 29; 21–40 y.o., <span class="html-italic">n</span> = 18), CCS of hematological tumors (hCCS; &lt;10 y.o., <span class="html-italic">n</span> = 25; 11–20 y.o., <span class="html-italic">n</span> = 28; 21–40 y.o., <span class="html-italic">n</span> = 22), healthy donors aged between 41–60 y.o., <span class="html-italic">n</span> = 19; healthy donors aged between 61–80 y.o., <span class="html-italic">n</span> = 25; healthy donors aged over 80 y.o., <span class="html-italic">n</span> = 22. Data reported in Panels (<b>C</b>–<b>F</b>) are representative of three independent experiments, each on <span class="html-italic">n</span> = 3 age-matched healthy donors (&lt;40 y.o); <span class="html-italic">n</span> = 3 (CCS &lt; 40 y.o.), and <span class="html-italic">n</span> = 3 elderly healthy subjects (&gt;60 y.o.). (<b>A</b>) SOD activity; (<b>B</b>) CAT activity; (<b>C</b>) Representative Western blot signals of SOD1 (cytosolic form), SOD2 (mitochondrial form), and CAT. Actin was evaluated as a housekeeping signal. (<b>D</b>) Densitometric analysis of SOD1 signal normalized against actin signal; (<b>E</b>) Densitometric analysis of SOD2 signal normalized against actin signal; (<b>F</b>) Densitometric analysis of CAT signal normalized against actin signal. ROD = Relative Optical Density. *, **** indicate a <span class="html-italic">p</span> &lt; 0.05, 0.0001. In panels (<b>A</b>,<b>B</b>), ##, and ### indicate a <span class="html-italic">p</span> &lt; 0.01, or 0.001, respectively, between sCCS or hCCS and healthy donors over 80 y.o.</p>
Full article ">Figure 5
<p>Nrf2 and KEAP1 protein expression in MNCs isolated from CCS, age-matched healthy subjects, and elderly healthy controls. Data reported in this figure are representative of three independent experiments, each on <span class="html-italic">n</span> = 3 age-matched healthy donors (&lt;40 y.o); <span class="html-italic">n</span> = 3 (CCS &lt; 40 y.o.), and <span class="html-italic">n</span> = 3 elderly healthy subjects (&gt;60 y.o.). (<b>A</b>) Representative Western blot signals of Nrf2 and KEAP1. Actin was evaluated as a housekeeping signal. (<b>B</b>) Densitometric analysis of Nrf2 signal normalized against actin signal; (<b>C</b>) Densitometric analysis of KEAP1 signal normalized against actin signal. ROD = Relative Optical Density. **, ***, **** indicate a <span class="html-italic">p</span> &lt; 0.01, 0.001, 0.0001. ns: not significant.</p>
Full article ">Figure 6
<p>Nrf2 and antioxidant enzymes protein expression in MNCs isolated from CCS before and after NAC treatment. Data reported in this figure are representative of three independent experiments, each on <span class="html-italic">n</span> = 3 CCS and <span class="html-italic">n</span> = 3 same CCS treated with NAC. (<b>A</b>) Representative Western blot signals of Nrf2, G6PD, H6PD, GR, GPx, SOD1, SOD2, and CAT. Actin was evaluated as a housekeeping signal. (<b>B</b>) Densitometric analysis of Nrf2 signal normalized against actin signal; (<b>C</b>) Densitometric analysis of G6PD signal normalized against actin signal; (<b>D</b>) Densitometric analysis of H6PD signal normalized against actin signal; (<b>E</b>) Densitometric analysis of GR signal normalized against actin signal; (<b>F</b>) Densitometric analysis of GPx signal normalized against actin signal; (<b>G</b>) Densitometric analysis of SOD1 (cytosolic form) signal normalized against actin signal; (<b>H</b>) Densitometric analysis of SOD2 (mitochondrial form) signal normalized against actin signal; (<b>I</b>) Densitometric analysis of CAT signal normalized against actin signal. ROD = Relative Optical Density. **** indicates a <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 7
<p>Antioxidant enzyme activities, OxPhos coupling, and oxidative damage accumulation in MNCs isolated from CCS before and after NAC treatment. Data reported in this figure were obtained on MNCs isolated from <span class="html-italic">n</span> = 20 CCS of solid tumor (sCCS; aged under 40 y.o.) and <span class="html-italic">n</span> = 22 CCS of hematological tumors (hCCS; aged under 40 y.o.) treated or not with NAC. (<b>A</b>) G6PD activity; (<b>B</b>) H6PD activity; (<b>C</b>) GR activity; (<b>D</b>) GPx activity; (<b>E</b>) SOD activity; (<b>F</b>) CAT activity; (<b>G</b>) ROS production; (<b>H</b>) P/O value as an OxPhos efficiency marker; (<b>I</b>) Malondialdehyde (MDA) intracellular concentration, as a lipid peroxidation marker; (<b>J</b>) 4-hydroxynonenal (4-HNE) intracellular concentration, as a lipid peroxidation marker; (<b>K</b>) 8-Hydroxy-2′-deoxyguanosine (8-OHdG) intracellular concentration, as a DNA oxidative damage marker; (<b>L</b>) Nitrotyrosine intracellular level, as a protein oxidative damage marker. **** indicates a <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">
26 pages, 735 KiB  
Article
Social Reintegration Experiences of Young Adult Cancer Survivors
by Ji Seong Yi and Song Yi Lee
Behav. Sci. 2024, 14(11), 1101; https://doi.org/10.3390/bs14111101 - 15 Nov 2024
Viewed by 424
Abstract
This study uses the Q methodology to investigate the subjective perceptions of social reintegration among cancer survivors in their 20s and 30s. We organised a Q population through a pilot study and interviews and finalised 40 Q sample items. For P sample representativeness, [...] Read more.
This study uses the Q methodology to investigate the subjective perceptions of social reintegration among cancer survivors in their 20s and 30s. We organised a Q population through a pilot study and interviews and finalised 40 Q sample items. For P sample representativeness, we used purposive sampling and selected 12 individuals by age and cancer type. After a Q sorting process, we conducted a key factor analysis using Ken-Q Analysis Desktop Edition. We identified four types of P samples based on their perceptions and noted the main characteristics of each type. We characterised Type 1 as “recovery of presence through social reintegration seeking”, Type 2 as “confusion in social reintegration due to social prejudices”, Type 3 as “psychosocial support in the process of social reintegration”, and Type 4 as “blessing in disguise for post-traumatic growth”. The results suggest a need for practical and institutional support reflecting cancer survivors’ characteristics by type. This study provides basic data that researchers could use to develop coaching and counselling services to support the social reintegration of cancer survivors in their 20s and 30s. Full article
(This article belongs to the Special Issue Narrative Approaches and Practice in Health Psychology)
Show Figures

Figure 1

Figure 1
<p>Q sorting distribution chart.</p>
Full article ">
9 pages, 10199 KiB  
Case Report
Breaking Through Resistance: Carbapenem-Resistant Nocardia?!—A Case Report
by Vlad-Sabin Ivan, Paul-Gabriel Ciubotaru, Liviu Cirin, Florin Giru, Dan Costachescu, Daniel-Florin Lighezan and Roxana Buzas
Medicina 2024, 60(11), 1863; https://doi.org/10.3390/medicina60111863 - 14 Nov 2024
Viewed by 323
Abstract
Nocardia is an emerging bacterial disease that often affects patients with compromised immune systems. As the number of patients undergoing solid organ transplants continues to rise, and as more cancer survivors are treated with long-term immune-modifying agents, corticosteroids, and immunosuppressive medications, organisms that [...] Read more.
Nocardia is an emerging bacterial disease that often affects patients with compromised immune systems. As the number of patients undergoing solid organ transplants continues to rise, and as more cancer survivors are treated with long-term immune-modifying agents, corticosteroids, and immunosuppressive medications, organisms that typically pose no harm are becoming a public health concern. Carbapenems are usually a second-line therapy in the setting of Nocardia infections. We present the case of a patient who had an immunocompromised status and was diagnosed with Nocardia farcinica, which showed in vitro resistance to carbapenems. The symptoms were non-specific and had a common presentation with headache, fatigue, and a nonresponsive cough to usual cough drugs, although the infection was disseminated and had severe CNS and ocular involvement. The clinical course worsened when the carbapenem was withdrawn and markedly improved when it was re-administered, although the initial antibiogram showed resistance to carbapenems. Despite the observed in vitro resistance in the laboratory, the re-administration of carbapenems was beneficial, as both inflammatory markers and clinical status showed improvement. This was based on clinical judgment, which carefully evaluated the associated risks and benefits. Also, this raises the question of potential risks to develop real resistance to carbapenems of some Nocardia species, which could pose a significant challenge to healthcare. It could become a serious healthcare problem in the future and should prompt active environmental testing. Full article
(This article belongs to the Section Hematology and Immunology)
Show Figures

Figure 1

Figure 1
<p>Initial cranial CT (no contrast).</p>
Full article ">Figure 2
<p>CT with contrast, showing disseminated lesions in the lungs, abdomen, and soft tissues (the green arrows indicate disseminated abscesses, blue arrow indicates drained abscess).</p>
Full article ">Figure 3
<p>MRI. (Ring-enhancing lesions are present in all cerebral lobes and the thalamus. Different sequences showing brain abscesses are indicated by green arrows; the star indicates eye involvement).</p>
Full article ">Figure 4
<p>Macroscopic aspect of the evacuated subcutaneous abscess (<b>right</b>) and microscopic aspect with ramified filamentous Gram-positive bacilli growing in an aerobic environment (<b>left</b>).</p>
Full article ">Figure 5
<p>CRP level dynamics (the spike indicates meropenem withdrawal and corroborates with the sharp increase in headache intensity and retroorbital pain).</p>
Full article ">Figure 6
<p>Follow-up Ct at three months. The chest CT does not show any cavitating lesions, with residual scarring and healing processes of the lesions.</p>
Full article ">
13 pages, 259 KiB  
Article
“It Was a Downward Spiral”: A Qualitative Study of Young Adult Cancer Survivors’ Experiences with Cognitive and Mental Health
by Danielle B. Tometich, Christina Hersh, Melinda L. Maconi, Hayden J. Fulton, Dinorah Martinez Tyson, Kellie Zambrano, Syed Hasan, Taylor Welniak, Yvelise Rodriguez, Crystal Bryant, Lisa M. Gudenkauf, Xiaoyin Li, Damon R. Reed, Laura B. Oswald, Andrew Galligan, Brent J. Small and Heather S. L. Jim
Cancers 2024, 16(22), 3819; https://doi.org/10.3390/cancers16223819 - 13 Nov 2024
Viewed by 328
Abstract
Background/Objectives: Cancer-related cognitive impairment (CRCI) is common and distressing for young adult (YA) cancer survivors; however, subjective CRCI is often attributed to psychological distress rather than true cognitive change. Thus, we aimed to generate hypotheses regarding potential common biobehavioral mechanisms of CRCI and [...] Read more.
Background/Objectives: Cancer-related cognitive impairment (CRCI) is common and distressing for young adult (YA) cancer survivors; however, subjective CRCI is often attributed to psychological distress rather than true cognitive change. Thus, we aimed to generate hypotheses regarding potential common biobehavioral mechanisms of CRCI and psychological distress. Methods: We conducted semi-structured interviews with YA cancer survivors in peak years for frontal neurocognitive development (ages 18–30), and we asked them to describe their experiences with cognitive and mental health changes during and after treatment for their cancer. An applied thematic analysis was used to identify themes. Results: The participants were 20 YA cancer survivors who were, on average, 23 years old at diagnosis and 26 years old when interviewed. Five themes emerged regarding the connection between cognitive and mental health: depressed mood after diagnosis that decreased mental engagement, cancer-related anxiety consumed cognitive resources during treatment, a bidirectional “downward spiral” during treatment, frustration with forgetfulness, and self-criticism about long-term cognitive limitations. Additionally, participants described receiving minimal information about evidence-based strategies for managing CRCI. Conclusions: Future research is needed to examine common neurological mechanisms among symptoms of depression, anxiety, and CRCI and to address gaps in survivorship care for YA survivors with CRCI. Cognitive–behavioral interventions may address both cognitive and mental health. Full article
(This article belongs to the Special Issue Novel Insights into Cancer-Related Cognitive Impairment)
10 pages, 630 KiB  
Article
Associations Between Dietary Patterns and Quality of Life in a Longitudinal Cohort of Colorectal Cancer Survivors
by Kristen S. Smith, Lisa M. Gudenkauf, Aasha I. Hoogland, Xiaoyin Li, Rachel Hoobler, Mary C. Playdon, Biljana Gigic, Brent J. Small, Brian D. Gonzalez, Laura B. Oswald, Doratha A. Byrd, K. Leigh Greathouse, Cornelia M. Ulrich, Christopher I. Li, David Shibata, Adetunji T. Toriola, Anita R. Peoples, Erin M. Siegel, Jane C. Figueiredo, Heather S. L. Jim and Sylvia L. Crowderadd Show full author list remove Hide full author list
Nutrients 2024, 16(22), 3860; https://doi.org/10.3390/nu16223860 - 12 Nov 2024
Viewed by 467
Abstract
Purpose: To characterize dietary patterns and examine associations with cross-sectional and longitudinal changes in quality of life (QOL) over approximately one year after colorectal cancer (CRC) diagnosis. Methods: The ColoCare Study is an international, multi-center, prospective cohort study of newly diagnosed CRC survivors [...] Read more.
Purpose: To characterize dietary patterns and examine associations with cross-sectional and longitudinal changes in quality of life (QOL) over approximately one year after colorectal cancer (CRC) diagnosis. Methods: The ColoCare Study is an international, multi-center, prospective cohort study of newly diagnosed CRC survivors of any stage. A subset of participants with CRC in the United States completed patient-reported outcome measures at 6- and 12-months post-enrollment, including the Food Frequency Questionnaire (FFQ) and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Dietary patterns at 6 months (around the time of treatment completion) were identified using Principal Component Analysis (PCA) with varimax rotation. Adherence scores were calculated for participants within each dietary pattern, with higher scores indicating higher adherence. Mixed models were used to examine the effect of each dietary pattern on changes in QOL at 6- and 12-month follow-ups, controlling for cancer stage, biological sex, body mass index (BMI), smoking status, and age. Results: Participants (N = 174) were, on average, 56 ± 14 years old and were mostly female (51.5%), stage III or IV (51.7%), never smokers (60.2%), non-Hispanic (97.1%), and White (83.3%) with a BMI of 27.9 ± 6.1 kg/m2. PCA revealed two emerging dietary patterns: “Western diet”, characterized by processed meats, refined grains, and sugars, and “Prudent diet” characterized by lean proteins, fruits, and vegetables. Higher adherence to a Western diet was associated with worse social functioning at 6-month follow-up (FE = −12.6, p = 0.010). Loss of appetite from 6 to 12 months was associated with higher adherence to both the Western and Prudent dietary patterns (FE = 1.5, p = 0.044; FE = 1.3, p = 0.046, respectively). Neither dietary pattern was associated with global QOL score at 6- or 12-month follow-up (p’s > 0.05). Conclusions: Among CRC survivors in the United States, the Western diet was concurrently associated with worse social functioning. Loss of appetite was reported by CRC survivors following both dietary patterns, suggesting that loss of appetite may be a global experience for CRC survivors during this timeframe. Further research is needed to understand specific social challenges experienced by CRC survivors and develop supportive care interventions to address appetite and nutritional concerns. Full article
Show Figures

Figure 1

Figure 1
<p>Changes in lack of appetite by level of adherence to a Western dietary pattern during transition off treatment in United States colorectal cancer survivors (<span class="html-italic">n</span> = 174).</p>
Full article ">Figure 2
<p>Changes in lack of appetite by level of adherence to a prudent dietary pattern during transition off treatment in United States colorectal cancer survivors (<span class="html-italic">n</span> = 174).</p>
Full article ">
10 pages, 240 KiB  
Brief Report
Impact of an Asian Community-Based Cancer Rehabilitation Program on Health-Related Quality of Life
by Matthew Rong Jie Tay, Chin Jung Wong and Vijayalaxmi Chadachan
Healthcare 2024, 12(22), 2251; https://doi.org/10.3390/healthcare12222251 - 11 Nov 2024
Viewed by 370
Abstract
Background/Objectives: Inpatient exercise-based rehabilitation has been shown to improve health-related quality of life (HRQOL) in cancer survivors. However, there is a lack of studies on the impact of community-based cancer rehabilitation programs on health-related quality of life, especially in Asian countries. Methods: This [...] Read more.
Background/Objectives: Inpatient exercise-based rehabilitation has been shown to improve health-related quality of life (HRQOL) in cancer survivors. However, there is a lack of studies on the impact of community-based cancer rehabilitation programs on health-related quality of life, especially in Asian countries. Methods: This was a retrospective cohort study involving patients with cancer at an outpatient community-based rehabilitation center. There were 197 patients who were recruited and enrolled in a physician-led rehabilitation program which included physiotherapists, occupational therapists, nutritionists and exercise physiologists. Results: Most of the patients had a diagnosis of breast cancer (61.4%), while 76 (38.6%) had a diagnosis of other cancers. On initial assessment, we found a mean Distress Thermometer (DT) level of 3.37 (SD = 2.41) and a mean Functional Assessment of Cancer Therapy-General-7 Item Version (FACT-G7) score of 11.83 (SD = 4.01). On follow-up assessment after 3–6 months of rehabilitation, there was a significant reduction in mean DT level to 2.42 (SD = 2.25) and an improvement in mean FACT-G7 score to 13.09 (SD = 4.77). Multivariate regression analysis revealed that significant factors for improvement in FACT-G7 scores were age (p = 0.046) and number of exercise therapy sessions (p < 0.001). Conclusions: This study demonstrates the positive impact of a community-based cancer rehabilitation program on HRQOL among cancer patients. Full article
(This article belongs to the Special Issue Multidisciplinary Approaches in Cancer Healthcare)
22 pages, 4211 KiB  
Article
Exploring Sex-Based Neuropsychological Outcomes in Pediatric Brain Cancer Survivors: A Pilot Study
by Chiara Colliva, Veronica Rivi, Pierfrancesco Sarti, Isabel Cobelli and Johanna M. C. Blom
Diseases 2024, 12(11), 289; https://doi.org/10.3390/diseases12110289 - 11 Nov 2024
Viewed by 367
Abstract
Background: The increasing survival rates among pediatric cancer patients underscore the critical need to understand the long-term psychosocial impacts of cancer treatments, such as cisplatin and carboplatin. While these treatments are lifesaving, they may pose risks to neurodevelopmental processes. Despite the substantial body [...] Read more.
Background: The increasing survival rates among pediatric cancer patients underscore the critical need to understand the long-term psychosocial impacts of cancer treatments, such as cisplatin and carboplatin. While these treatments are lifesaving, they may pose risks to neurodevelopmental processes. Despite the substantial body of research highlighting cognitive impairments associated with cancer treatments, there remains a gap in understanding how these effects differ by sex. As sex differences could inform tailored interventions and support mechanisms for affected individuals, this pilot study aimed to examine the sex differences in neuropsychological outcomes in patients treated for brain cancer with cisplatin and/or carboplatin. Methods: Our study employed rigorous/structured neuropsychological assessments to evaluate executive functions in pediatric cancer survivors treated with cisplatin and/or carboplatin. We utilized the BRIEF and TOL tests to assess the key domains of executive function, including inhibitory control, cognitive flexibility, and problem-solving abilities. Additionally, psychosocial factors were evaluated using the Resiliency Scale to measure resilience and the PAT test to assess family psychosocial risk. Results: In our cohort of 17 patients, significant sex differences emerged, where males outperformed females in areas such as inhibitory control, impulse regulation, and strategic planning. Conclusions: These findings highlight the complexity of cognitive outcomes in pediatric cancer survivors. Understanding sex-specific differences is essential for developing tailored interventions that optimize cognitive and psychosocial outcomes. Future research should focus on larger cohorts and longitudinal studies to validate these findings and guide targeted interventions to improve survivorship outcomes. Full article
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>) PAT scores in males and females. (<b>B</b>) A total of 80.00% were categorized as part of the universal group, while 20.00% were classified as part of the targeted one. (<b>C</b>) The pie chart designates male categorization, showing that 50.00% were part of the universal population and 50.00% were part of the targeted one. Comparisons were made by an unpaired <span class="html-italic">t</span>-test. The thicker line is the mean, and the error bars are the s.e.m.s.</p>
Full article ">Figure 2
<p>BRIEF variables’ scores were measured in the sample separately for the females (white bar) and males (diagonal bars). Significant differences between the females and males in the BRIEF inhibit (<b>A</b>), initiate (<b>D</b>), and plan/organize (<b>F</b>) scores emerged. However, no significant differences were found in the BRIEF shift, emotional control (EMO—(<b>C</b>)), working memory (WM—(<b>D</b>)), and monitor (<b>G</b>) scores. For the broader indexes, the BRI scores (<b>H</b>) showed no significant difference between the females and males, while the MI scores (<b>I</b>) revealed a significant difference between the sexes. No effects were found in the (<b>B</b>) SHIF and (<b>E</b>) WM, Comparisons were made by an unpaired <span class="html-italic">t</span>-test. The thicker line is the mean, and the error bars are the s.e.m.s., ** <span class="html-italic">p</span> &lt; 0.01, * <span class="html-italic">p</span> &lt; 0.05. The normative scores are represented by the dashed line.</p>
Full article ">Figure 3
<p>The TOL variables’ scores (<b>A</b>–<b>E</b>) TOL violation, TOL decision time, TOT execution time, TOT time, ACCURACY) were measured in the sample separately for the females (white bar) and males (diagonal bars). No significant differences between the females and males emerged. Comparisons were made by an unpaired <span class="html-italic">t</span>-test. The thicker line is the mean, and the error bars are the s.e.m.s. The normative scores are represented by the dashed line.</p>
Full article ">Figure 4
<p>The females’ (white bar) and males’ (diagonal bars) scales in the different resiliency subscales: the sense of mastery scale (MAS—(<b>A</b>)), the sense of relatedness scale (REL—(<b>B</b>)), the emotional reactivity scale (REA—(<b>C</b>)), and the general vulnerability index (VUL—(<b>D</b>)). No significant differences between the females and males emerged. The comparisons were made by an unpaired <span class="html-italic">t</span>-test. The thicker dashed line is the mean, and the error bars are the s.e.m.s. The normative scores are represented by the dashed line.</p>
Full article ">Figure 5
<p>Representation of the network model of the 17 patients. The nodes are the variables while the edges are partial correlations between them. Green edges are positive and red are negative. Gray edges represent a point-biserial correlation between a continuous and a dichotomous variable. The thickness of the edge represents the strength of that correlation. The ring around each variable is the predictability value.</p>
Full article ">Figure 6
<p>Moderated Gaussian Graphical Model. The two networks represent the same model but moderating the variable 2 (sex) in terms of 1 or 2 (females and males). The edges represent the conditional dependencies between variables. Red ones are negative and blue ones are positive.</p>
Full article ">Figure 7
<p>Cartesian representation of the three variables that had the most impact on the risk scores of the patients. Each dot represents a patient. The scores of the variables PAT, initiate, and plan/organize were impaired. The higher it was, the more negative it was.</p>
Full article ">
20 pages, 609 KiB  
Article
Diet Quality and Dietary Intake in Breast Cancer Survivors Suffering from Chronic Pain: An Explorative Case-Control Study
by Sevilay Tümkaya Yılmaz, Ömer Elma, Jo Nijs, Peter Clarys, Iris Coppieters, Tom Deliens, Patrick Calders, Eline Naert and Anneleen Malfliet
Nutrients 2024, 16(22), 3844; https://doi.org/10.3390/nu16223844 - 9 Nov 2024
Viewed by 614
Abstract
Background/Objectives: Dietary factors may significantly influence pain management in cancer survivors. However, a substantial gap exists regarding the relationship between nutrition and chronic pain in this population. This study examined differences in diet quality and dietary intake between breast cancer survivors (BCS) experiencing [...] Read more.
Background/Objectives: Dietary factors may significantly influence pain management in cancer survivors. However, a substantial gap exists regarding the relationship between nutrition and chronic pain in this population. This study examined differences in diet quality and dietary intake between breast cancer survivors (BCS) experiencing chronic pain and healthy controls (HC). It also aimed to understand the associations between dietary elements and pain-related outcomes within the BCS group. Methods: A case-control study was conducted with 12 BCS experiencing chronic pain and 12 HC (ages 18–65). Data collection included body composition, experimental pain assessments, pain-related questionnaires, and a 3-day food diary to calculate diet quality using the Healthy Eating Index-2015 (HEI-2015) and Dietary Inflammatory Index (DII). Statistical analyses evaluated group differences and associations between dietary factors and pain within the BCS group. Results: There were no significant differences in HEI-2015 scores between BCS and HC, but BCS had a significantly lower DII score (p = 0.041), indicating a more anti-inflammatory diet. BCS also showed higher intake of omega-3, vitamins B6, B12, A, D, and magnesium (p < 0.05). While total diet quality scores did not correlate with pain outcomes, several HEI-2015 and DII components, such as dairy, sodium, protein, vitamin C, and vitamin D, showed moderate positive or negative correlations with pain measures. Conclusions: Despite no overall differences in diet quality, BCS with chronic pain consumed more anti-inflammatory nutrients than HC. Complex correlations between specific dietary components and pain outcomes emphasise the need for further research to explore these links for chronic pain management in BCS. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Flow of the study. * Test side changes were separated by a 30-s rest period within the measurement.</p>
Full article ">
17 pages, 307 KiB  
Review
Cancer-Related Cognitive Impairments (CRCIs) in Non-Central Nervous System Adult Patients: Outcome Measures and Methodology of Assessment: A Literature Review
by Andrea Pace, Antonio Tanzilli, Enrico Marchioni, Alessia Pellerino, Antonino Carmelo Tralongo, Paola Bini, Paolo Tralongo and Stefano Francesco Cappa
Brain Sci. 2024, 14(11), 1119; https://doi.org/10.3390/brainsci14111119 - 4 Nov 2024
Viewed by 586
Abstract
Background: Cancer-related cognitive impairment (CRCI) represents one of the most common and debilitating effects in patients surviving after cancer treatments. Neurocognitive deficits are important causes of disability and burden in cancer survivors. The true magnitude of CRCI is difficult to define due to [...] Read more.
Background: Cancer-related cognitive impairment (CRCI) represents one of the most common and debilitating effects in patients surviving after cancer treatments. Neurocognitive deficits are important causes of disability and burden in cancer survivors. The true magnitude of CRCI is difficult to define due to significant heterogeneity of literature data. At present, there is no agreement on the gold standard for detection and grading of CRCI in clinical trials, and there is a lack of clear knowledge of its pathophysiology. Objectives: In this review, we aim to discuss some perspectives for future research to pursue in order to cover the gaps in knowledge in the CRCI field. Methods: We focused our literature research on the following relevant issues: neuroradiological correlates of CRCI; objective neuropsychological evaluation and subjective complaint assessment and their correlation with objective measures; timing of assessment; and possible treatments. Results: The correct methodology for evaluating cognitive deficits induced by anti-tumor treatments still requires a definition based on quality scientific evidence, and literature data are currently scarce. Conclusions: This review highlights the need for further research to understand the causes and consequences of cancer-related cognitive impairment using standardized and sensitive measures of cognitive functions and the long-term effects of chemotherapy on cognitive functions and to develop effective interventions. Full article
(This article belongs to the Special Issue Neurotoxicities from Cancer Immunotherapies)
20 pages, 463 KiB  
Review
Nutrition Modulation of Cardiotoxicity in Breast Cancer: A Scoping Review
by Emma Stephenson, Marie Mclaughlin, James W. Bray, John M. Saxton and Rebecca V. Vince
Nutrients 2024, 16(21), 3777; https://doi.org/10.3390/nu16213777 - 3 Nov 2024
Viewed by 971
Abstract
Background/Objectives: Advancements in breast cancer therapeutics, such as anthracyclines, are improving cancer survival rates but can have side effects that limit their use. Cardiotoxicity, defined as damage to the heart caused by cancer therapeutics, is characterised by a significant reduction in left ventricular [...] Read more.
Background/Objectives: Advancements in breast cancer therapeutics, such as anthracyclines, are improving cancer survival rates but can have side effects that limit their use. Cardiotoxicity, defined as damage to the heart caused by cancer therapeutics, is characterised by a significant reduction in left ventricular ejection fraction (LVEF) and symptoms of cardiac dysfunction. Multiple oral supplements exist with antioxidant and anti-inflammatory properties that have the potential to lower cardiotoxicity risk and ameliorate the complications associated with left ventricular dysfunction. In this review, we evaluate the current status of using nutritional interventions to modulate cardiotoxicity. Methods: We used specific keywords to search for articles that met our predetermined inclusion and exclusion criteria to review the evidence and provide insights for future research. Results: Seven studies were identified as eligible for this review: six focused on oral supplementation strategies in breast cancer patients undergoing chemotherapy, and one focused on nutritional counselling and adherence to the Mediterranean diet in breast cancer survivors’ post-treatment. There was a significantly attenuated reduction in LVEF in five studies that monitored cardiometabolic health, and there were significant improvements in blood serum levels of cardiac biomarkers across all studies. Conclusions: Current evidence suggests that appropriate nutritional interventions, alongside chemotherapy, can modulate the risk of cardiotoxic side effects. This highlights the potential of oral antioxidant supplementation and Mediterranean diet counselling to decrease tertiary cancer therapy costs associated with cardiovascular complications. Full article
(This article belongs to the Special Issue Nutrition, Physical Activity and Chronic Disease—2nd Edition)
Show Figures

Figure 1

Figure 1
<p>Flow diagram of identification, screening, and inclusion of studies.</p>
Full article ">
24 pages, 1474 KiB  
Article
Development, Content Validity and Usability of a Self-Assessment Instrument for the Lifestyle of Breast Cancer Survivors in Brazil
by Jaqueline Schroeder de Souza, Nathalie Kliemann, Francilene Gracieli Kunradi Vieira, Aline Al Nahas, Luiza Kuhnen Reitz, Elom Kouassivi Aglago, Cândice Laís Knöner Copetti, Lilian Cardoso Vieira, Inge Huybrechts, Nivaldo Barroso de Pinho and Patricia Faria Di Pietro
Nutrients 2024, 16(21), 3707; https://doi.org/10.3390/nu16213707 - 30 Oct 2024
Viewed by 579
Abstract
Background/Objectives: Breast cancer is the most common cancer among women globally, and it negatively impacts diet and quality of life, increasing the risk of recurrence. Adhering to World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR) lifestyle guidelines, such as [...] Read more.
Background/Objectives: Breast cancer is the most common cancer among women globally, and it negatively impacts diet and quality of life, increasing the risk of recurrence. Adhering to World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR) lifestyle guidelines, such as healthy eating habits and nutritional status, can help in primary and secondary cancer prevention. However, no questionnaire was found for self-assessment of these guidelines for the Brazilian population. The aim of this study is to carry out content validity, pilot, and usability testing of the self-administered digital instrument “PrevCancer” assessing adherence to the WCRF/AICR recommendations in Brazilian female breast cancer survivors. Methods: We conducted a psychometric study that involved the development of an instrument based on WCRF/AICR recommendations. Assessment of content validity involved the Content Validity Index (CVI) based on expert assessments (n = 7). The pilot study involved the System Usability Scale (SUS) after applying the developed instrument (n = 65) and anthropometric assessment for convergent validity by female participants (n = 55). The final usability test consisted of evaluating the satisfaction with the instrument of women with breast cancer (n = 14). Results: The “PrevCancer” instrument demonstrated good content (CVI = 1.0) as well as good usability and acceptability in the pilot study (mean SUS score = 88.1). The convergent validity stage demonstrated positive associations between the PrevCancer parameters and anthropometric parameters (p < 0.001). In the final usability study (mean SUS score = 90.3), participants’ receptivity to the instrument was excellent. Conclusions: The PrevCancer instrument had valid content and great usability by the target population, proving to be a useful tool for future cancer research. Full article
(This article belongs to the Special Issue Dietary Approaches and Prevention of Chronic Diseases)
Show Figures

Figure 1

Figure 1
<p>Diagram with the phases of the study. <sup>a</sup> All items related to the instrument development consisted of methodological stages of the study. An initial version of the instrument was structured on the Google Forms platform to be subjected to pilot study. <sup>b</sup> Pilot study conducted with an initial version of the instrument structured in Google Forms. <sup>c</sup> The partial version of the instrument was replaced by the official platform version from step 3 onwards.</p>
Full article ">Figure 2
<p>Bland and Altman graphs on the relationship between the reference method and PrevCancer instrument parameter. (<b>a</b>) Relationship between measured and automatically calculated BMI in the PrevCancer instrument. (<b>b</b>) Relationship between measured and automatically calculated body weight in the PrevCancer instrument.</p>
Full article ">Figure 3
<p>PrevCancer website layout example (adapted to English language), a self-assessment tool for the lifestyle assessment of breast cancer survivors.</p>
Full article ">
14 pages, 2088 KiB  
Article
From Real-World Data to Causally Interpretable Models: A Bayesian Network to Predict Cardiovascular Diseases in Adolescents and Young Adults with Breast Cancer
by Alice Bernasconi, Alessio Zanga, Peter J. F. Lucas, Marco Scutari, Serena Di Cosimo, Maria Carmen De Santis, Eliana La Rocca, Paolo Baili, Ilaria Cavallo, Paolo Verderio, Chiara M. Ciniselli, Sara Pizzamiglio, Adriana Blanda, Paola Perego, Paola Vallerio, Fabio Stella, Annalisa Trama and The Ada Working Group
Cancers 2024, 16(21), 3643; https://doi.org/10.3390/cancers16213643 - 29 Oct 2024
Viewed by 604
Abstract
Background: In the last decades, the increasing number of adolescent and young adult (AYA) survivors of breast cancer (BC) has highlighted the cardiotoxic role of cancer therapies, making cardiovascular diseases (CVDs) among the most frequent, although rare, long-term sequalae. Leveraging innovative artificial [...] Read more.
Background: In the last decades, the increasing number of adolescent and young adult (AYA) survivors of breast cancer (BC) has highlighted the cardiotoxic role of cancer therapies, making cardiovascular diseases (CVDs) among the most frequent, although rare, long-term sequalae. Leveraging innovative artificial intelligence (AI) tools and real-world data (RWD), we aimed to develop a causally interpretable model to identify young BC survivors at risk of developing CVDs. Methods: We designed and trained a Bayesian network (BN), an AI model, making use of expert knowledge and data from population-based (1036 patients) and clinical (339 patient) cohorts of female AYA (i.e., aged 18 to 39 years) 1-year survivors of BC, diagnosed in 2009–2019. The performance achieved by the BN model was validated against standard classification metrics, and two clinical applications were proposed. Results: The model showed a very good classification performance and a clear causal semantic. According to the predictions made by the model, focusing on the 25% of AYA BC survivors at higher risk of developing CVDs, we could identify 81% of the patients who would actually develop it. Moreover, a desktop-based app was implemented to calculate the individual patient’s risk. Conclusions: In this study, we developed the first causal model for predicting the CVD risk in AYA survivors of BC, also proposing an innovative AI approach that could be useful for all researchers dealing with RWD. The model could be pivotal for clinicians who aim to plan personalized follow-up strategies for AYA BC survivors. Full article
(This article belongs to the Special Issue Advances in Cancer Data and Statistics)
Show Figures

Figure 1

Figure 1
<p>Final Bayesian network model structure. The figure illustrates the directed acyclic graph behind the model. Briefly, the cohort of origin is set as the root context node, followed by three subsequent lines that illustrate the cancer prognostic factors which affect both the 5-year survival and treatment decisions (neoadjuvant if pre-surgery, or adjuvant if post-surgery). Type 2 diabetes (t2db), dyslipidemia, and hypertension (bottom right in the figure) can already be present prior to the cancer diagnosis or can be induced by the cancer treatments. Finally, at the bottom of the model, the nodes can be seen describing cardiotoxicity induced by treatments and ischemic heart diseases, pointing to the target variable (i.e., cardiovascular diseases (CVDs)).</p>
Full article ">Figure 2
<p>Bayesian network classification performances. Each classification metric is represented by a bar and the error bars are the 95% confidence intervals. Generally speaking, the model had good classification performances (AUC = 88% and accuracy = 99%). The model showed an almost perfect ability to correctly predict survivors not developing a CVD as not at risk (TNR, NPV), while identifying those developing a CVD as at risk is more complex due to the outcome rarity (TPR). When class imbalance is taken into consideration (BA and MCC), the performances decrease but remain very high (&gt;80%).</p>
Full article ">Figure 3
<p>Lift chart obtained using Bayesian network model predictions. In this graph, survivors are sorted (<span class="html-italic">x</span>-axis), in decreasing order, according to their risk of developing a cardiovascular disease (CVD). While the cumulative distribution of the survivors increases, the corresponding True Positive Rate (i.e., the proportion of survivors in the validation set who actually developed a CVD within 5 years) is plotted on the <span class="html-italic">y</span>-axis. The sharp rise in the lift chart highlights the model’s good ability to identify survivors who should be prioritized for CVD follow-up.</p>
Full article ">Figure 4
<p>Concept draft of the interface (<b>a</b>) and the output (<b>b</b>) of the app-based tool. The figure illustrates the interface of the desktop-based app based on Bayesian network model probabilities. When the user inputs the patient’s information into the data entry window (<b>a</b>), the baseline model probability estimates for the 5-year cardiovascular disease risk are updated. Subsequently, in a new window (<b>b</b>), the user is provided with the individual predicted patient probability, together with an illustration that helps the user interpret the predicted value according to the risk classes.</p>
Full article ">
Back to TopTop